Pearl River Capital, LLC Acadia Pharmaceuticals Inc Transaction History

Pearl River Capital, LLC

$0
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.79 - $30.86 $377,948 - $655,620	-21,245 Reduced 64.06%	11,920 $220,000
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $31,918 - $48,798	1,536 Added 4.86%	33,165 $1.04 Million
Q3 2023 Nov 13, 2023	BUY	$20.84 - $33.47 $57,789 - $92,812	2,773 Added 9.61%	31,629 $659,000
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $49,128 - $70,794	-2,760 Reduced 8.73%	28,856 $691,000
Q1 2023 Dec 19, 2024	BUY	$16.32 - $20.92 $515,973 - $661,406	31,616 New	31,616 $595,000
Q1 2023 May 12, 2023	BUY	$16.32 - $20.92 $233,767 - $299,658	14,324 Added 82.84%	31,616 $595,000
Q4 2022 Feb 13, 2023	SELL	$14.2 - $18.63 $182,129 - $238,948	-12,826 Reduced 42.59%	17,292 $275,000
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $227,608 - $294,713	16,131 Added 115.33%	30,118 $493,000
Q2 2022 Aug 12, 2022	SELL	$13.01 - $27.22 $123,087 - $257,528	-9,461 Reduced 40.35%	13,987 $197,000
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $294,395 - $386,622	14,059 Added 149.74%	23,448 $568,000
Q4 2021 Feb 11, 2022	BUY	$16.79 - $27.09 $157,641 - $254,348	9,389 New	9,389 $219,000
Q1 2021 May 14, 2021	SELL	$25.02 - $54.99 $178,968 - $393,343	-7,153 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$41.04 - $56.79 $347,321 - $480,613	-8,463 Reduced 54.19%	7,153 $382,000
Q3 2020 Nov 13, 2020	BUY	$36.42 - $57.0 $406,847 - $636,747	11,171 Added 251.32%	15,616 $644,000
Q2 2020 Aug 10, 2020	BUY	$39.26 - $52.73 $174,510 - $234,384	4,445 New	4,445 $215,000
Q1 2019 May 02, 2019	SELL	$16.17 - $27.38 $11,610 - $19,658	-718 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$14.32 - $22.92 $10,281 - $16,456	718 New	718 $12,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pearl River Capital, LLC with notifications on news.

Account